BioSpace News Archive

Dyne Therapeutics, Inc today announced that management is scheduled to participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference being held in New York, NY on Tuesday, October 4, 2022 at 8:00 a.m. ET.

Mindset Pharma Inc. today announced an exclusive licensing agreement for Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) to acquire intellectual property rights for a subset of Mindset’s preclinical compounds (the “Agreement”).

Invitae today announced the company has received a three-year appointment to a National Quality Forum (NQF) committee that provides input on recommendations for quality standards that impact how healthcare is delivered.

CraniUS LLC, an R&D company focused on building groundbreaking treatments for patients with chronic brain disease, announced the closing of a $19.4 million Series A fundraising round.

Amedisys, Inc., a leading home health, hospice, personal care and high-acuity care company, announced that Adam Holton will join the Company as Chief People Officer.

Synthetic Biologics, Inc. today announced a positive outcome from the Data and Safety Monitoring Committee (DSMC) review of results from the first Cohort of its Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD).

PaxMedica, Inc. provided a corporate update after the Company’s initial public offering, which closed on August 26, 2022.

Metabolon, Inc. announced a new partnership with the Lee Kong Chian School of Medicine at Nanyang Technological University, Singapore to identify biomarkers using data from the Health for Life in Singapore study.

TAAV Biomanufacturing Solutions, SL (TAAV) announced today the anticipated first use in a clinical trial of company-manufactured doggybone DNA™ (dbDNA™)1, a precisely engineered synthetic DNA material.

Nykode Therapeutics ASA announced positive clinical results from the Phase 1/2 open label, dose escalation trial of Nykode’s T cell focused pan-SARS-CoV-2 vaccine candidate in healthy individuals who were previously vaccinated with an approved mRNA vaccine.